{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:40:20Z","timestamp":1794861620310,"version":"4.9.1"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Iptacopan is a first\u2010in\u2010class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement\u2010driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed a global, multicenter, phase 2 basket study enrolling patients with primary ITP or CAD after failure of \u2265\u20091 unique prior therapies. Primary endpoints were platelet response (\u2265\u200950\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L) for ITP and hemoglobin response (\u2265\u20091.5\u2009g\/dL increase) for CAD sustained for \u2265\u20092 consecutive weeks during the first 12\u2009weeks of iptacopan treatment, without the use of rescue therapy. Other endpoints included time to first response, duration of response, pharmacokinetics, safety\/tolerability, and FACIT\u2010Fatigue. Nineteen patients were treated with iptacopan (9 ITP, 10 CAD). Among patients with CAD, most showed improvements in hemoglobin levels, with a mean increase of 2.2\u2009g\/dL from baseline to week 12; five (50%) patients achieved the primary endpoint. Improvements were also observed for other outcomes in CAD, including lactate dehydrogenase, bilirubin, reticulocytes, and FACIT\u2010Fatigue. Conversely, no patients with ITP met the primary endpoint. Most treatment\u2010emergent adverse events (TEAEs) were mild, the most common being headache (21%), asthenia (16%), fatigue (16%), and petechiae (16%). Iptacopan monotherapy demonstrated encouraging preliminary efficacy in primary CAD, while no protocol\u2010defined responses were observed in primary ITP. Iptacopan may represent a promising oral option for CAD and was well tolerated in both ITP and CAD with no unexpected safety signals.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: NCT05086744\n                  <\/jats:p>","DOI":"10.1002\/ajh.70147","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T04:51:01Z","timestamp":1765342261000},"page":"242-254","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"first","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[{"name":"Department of Hematology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ademokun","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Jang","sequence":"additional","affiliation":[{"name":"Samsung Medical Center  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-7037","authenticated-orcid":false,"given":"Maria Luisa","family":"Lozano","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigaci\u00f3n Sanitaria (IMIB)\u2010Pascual Parrilla Universidad de Murcia  Murcia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Valcarcel","family":"Ferreiras","sequence":"additional","affiliation":[{"name":"Hematology Department, Vall Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-4886","authenticated-orcid":false,"given":"Cristina","family":"Pascual\u2010Izquierdo","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda Hospital General Universitario Gregorio Mara\u00f1on, Instituto de Investigaci\u00f3n Gregorio Mara\u00f1on  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shripad","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Matviykiv","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vitaliti","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Chen","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research Co Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Katsanou","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Chawla","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al\u2010Samkari","sequence":"additional","affiliation":[{"name":"Division of Hematology, Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003686"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683416"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07995.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13475"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12388"},{"key":"e_1_2_12_8_1","first-page":"20","article-title":"Complement Blockade With C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia","volume":"12","author":"Roesch E.","year":"2016","journal-title":"American Journal of Hematology\/Oncology"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006864"},{"key":"e_1_2_12_10_1","unstructured":"National Organization for Rare Disorders \u201cCold Agglutinin Disease\u2014Affected Populations (Internet) \u201d2023accessed October 19 2024 https:\/\/rarediseases.org\/rare\u2010diseases\/cold\u2010agglutinin\u2010disease\/#affected."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S177621"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024190"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-856930"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022549"},{"key":"e_1_2_12_17_1","unstructured":"Sanofi FDA Approves Enjaymo After Pivotal Study Results accessed October 24 2024 https:\/\/www.sanofi.com\/en\/media\u2010room\/press\u2010releases\/2022\/2022\u201002\u201004\u201022\u201000\u201000\u20102379517."},{"key":"e_1_2_12_18_1","unstructured":"Sanofi \u201cPress Release: European Commission Approves Enjaymo (sutimlimab) for Treatment of Hemolytic Anemia in Adult Patients With Cold Agglutinin Disease \u201d2022 https:\/\/www.sanofi.com\/en\/media\u2010room\/press\u2010releases\/2022\/2022\u201011\u201017\u201017\u201050\u201000\u20102558583."},{"key":"e_1_2_12_19_1","unstructured":"Pharma Japan \u201cMHLW Panel Endorses Sanofi's Sutimlimab as Japan's First CAD Therapy \u201d2022 https:\/\/pj.jiho.jp\/article\/246841."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02627.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537974"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa230869"},{"key":"e_1_2_12_25_1","unstructured":"\u201cNovartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults With PNH | Novartis \u201daccessed March 28 2025 https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010receives\u2010fda\u2010approval\u2010fabhalta\u2010iptacopan\u2010offering\u2010superior\u2010hemoglobin\u2010improvement\u2010absence\u2010transfusions\u2010first\u2010oral\u2010monotherapy\u2010adults\u2010pnh."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027"},{"key":"e_1_2_12_27_1","unstructured":"\u201cNovartis Receives FDA Accelerated Approval for Fabhalta (iptacopan) the First and Only Complement Inhibitor for the Reduction of Proteinuria in Primary IgA Nephropathy (IgAN) | Novartis \u201daccessed March 28 2025 https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010receives\u2010fda\u2010accelerated\u2010approval\u2010fabhalta\u2010iptacopan\u2010first\u2010and\u2010only\u2010complement\u2010inhibitor\u2010reduction\u2010proteinuria\u2010primary\u2010iga\u2010nephropathy\u2010igan."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.09.017"},{"key":"e_1_2_12_29_1","unstructured":"\u201cNovartis Receives Third FDA Approval for Oral Fabhalta (Iptacopan)\u2014the First and Only Treatment Approved in C3 Glomerulopathy (C3G) | Novartis \u201daccessed March 28 2025 https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010receives\u2010third\u2010fda\u2010approval\u2010oral\u2010fabhalta\u2010iptacopan\u2010first\u2010and\u2010only\u2010treatment\u2010approved\u2010c3\u2010glomerulopathy\u2010c3g#:%7e:text=Basel%252C%20March%2020%252C%202025%20%25E2%2580%2593%20Novartis%20today%20announced%2cand%20only%20treatment%20approved%20for%20this%20condition%201\u20104."},{"key":"e_1_2_12_30_1","unstructured":"\u201cFACIT\u2010Fatigue \u201daccessed October 24 2024 https:\/\/www.facit.org\/measures\/facit\u2010fatigue."},{"key":"e_1_2_12_31_1","unstructured":"Q. A.Hill A.R\u00f6th B.Jilma et\u00a0al. \u201cClinically Important Change in FACIT\u2010Fatigue Score for Patients With Cold Agglutinin Disease: An Analysis Using the Phase 3 Cardinal and Cadenza Studies \u201dEuropean Hematology Association Virtual Congress 2021 Abstract EP1179."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13903"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2025.1490130"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006960"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20203110S155c"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab121.005"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00028-4"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747594"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732146"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T09:01:31Z","timestamp":1767603691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/ajh.70147"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70147","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"2025-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}